Sequential treatment of metastatic renal cancer in a complex evolving landscape.
作者信息
Angulo Javier C, Lawrie Charles H, López José I
机构信息
Clinical Department, Faculty of Biomedical Sciences, European University of Madrid, Getafe, Madrid, Spain.
Molecular Oncology, Biodonostia Research Institute, San Sebastián, Spain.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S272. doi: 10.21037/atm.2019.12.05.
Abstract
摘要
相似文献
1
Sequential treatment of metastatic renal cancer in a complex evolving landscape.在复杂多变的情况下对转移性肾癌进行序贯治疗。
Ann Transl Med. 2019 Dec;7(Suppl 8):S272. doi: 10.21037/atm.2019.12.05.
2
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.血管内皮生长因子（VEGF）抑制治疗后进展的晚期肾细胞癌患者的治疗格局演变
J Kidney Cancer VHL. 2017 May 11;4(2):10-18. doi: 10.15586/jkcvhl.2017.69. eCollection 2017.
3
The evolving landscape of metastatic renal cell carcinoma.转移性肾细胞癌的不断演变态势
Am Soc Clin Oncol Educ Book. 2012:299-302. doi: 10.14694/EdBook_AM.2012.32.25.
4
Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?转移性肾细胞癌不断变化的治疗格局：我们目前处于什么阶段？
Expert Rev Anticancer Ther. 2016;16(2):133-5. doi: 10.1586/14737140.2016.1132165. Epub 2016 Jan 28.
5
The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer.转移性分化型甲状腺癌的治疗格局演变
J Adv Pract Oncol. 2014 Nov-Dec;5(6):461-5. doi: 10.6004/jadpro.2014.5.6.7.
6
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.透明细胞转移性肾细胞癌转移灶与原发灶的靶向基因组图谱比较。
Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.
7
Evolving treatment landscape for early and advanced pancreatic cancer.早期和晚期胰腺癌不断演变的治疗格局。
World J Gastrointest Oncol. 2017 Jul 15;9(7):281-292. doi: 10.4251/wjgo.v9.i7.281.
8
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.2018 年转移性透明细胞肾细胞癌的系统治疗：当前范例、免疫治疗的应用及未来方向。
Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13.
9
Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?转移性胰腺癌的当前及不断发展的治疗方法：我们是否仍局限于细胞毒性化疗？
J Oncol Pract. 2016 Sep;12(9):797-805. doi: 10.1200/JOP.2016.015586.
10
Gastric cancer: current and evolving treatment landscape.胃癌：当前及不断演变的治疗格局。
Chin J Cancer. 2016 Aug 31;35(1):83. doi: 10.1186/s40880-016-0147-6.
引用本文的文献
1
Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy.预测接受基于VEGFR-TKI的序贯治疗的转移性透明细胞肾细胞癌的生存率
Cancers (Basel). 2024 Aug 7;16(16):2786. doi: 10.3390/cancers16162786.
2
Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.透明细胞肾细胞癌患者的皮肤转移与长期生存
Cureus. 2022 Mar 29;14(3):e23598. doi: 10.7759/cureus.23598. eCollection 2022 Mar.
3
Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.透明细胞肾细胞癌（CCRC）的抗血管生成治疗：药理学基础与临床结果
Cancers (Basel). 2021 Nov 24;13(23):5896. doi: 10.3390/cancers13235896.
4
Metastasis, an Example of Evolvability.转移，作为可进化性的一个例子。
Cancers (Basel). 2021 Jul 21;13(15):3653. doi: 10.3390/cancers13153653.
5
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.可溶性程序性死亡受体配体1是透明细胞肾细胞癌的独立预后因素。
Cancers (Basel). 2021 Feb 7;13(4):667. doi: 10.3390/cancers13040667.
6
Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices.推进肾细胞癌的科学研究与管理：弥合学术实践与社区实践之间的差距。
J Clin Med. 2020 May 17;9(5):1508. doi: 10.3390/jcm9051508.
7
The Labyrinth of Renal Cell Carcinoma.肾细胞癌的迷宫
Cancers (Basel). 2020 Feb 24;12(2):521. doi: 10.3390/cancers12020521.
本文引用的文献
1
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.透明细胞肾细胞癌中的肿瘤微环境动态。
Cancer Discov. 2019 Oct;9(10):1349-1357. doi: 10.1158/2159-8290.CD-19-0499. Epub 2019 Sep 16.
2
The Changing Therapeutic Landscape of Metastatic Renal Cancer.转移性肾癌不断变化的治疗格局
Cancers (Basel). 2019 Aug 22;11(9):1227. doi: 10.3390/cancers11091227.
3
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的系统治疗的测序和联合应用。
Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1.
4
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study.舒尼替尼治疗晚期肾细胞癌的再挑战：一项多中心回顾性研究的结果。
Cancer Chemother Pharmacol. 2019 Oct;84(4):781-789. doi: 10.1007/s00280-019-03913-3. Epub 2019 Jul 31.
5
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.转移性透明细胞肾细胞癌患者的长期生存。344 例患者真实研究结果。
Int J Cancer. 2020 Mar 15;146(6):1643-1651. doi: 10.1002/ijc.32578. Epub 2019 Aug 1.
6
Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.细胞因子与一线舒尼替尼及二线阿昔替尼治疗转移性肾细胞癌患者的疗效和安全性（ESCAPE研究）：一项III期随机序贯开放标签研究的研究方案
Contemp Clin Trials Commun. 2019 Jun 26;15:100403. doi: 10.1016/j.conctc.2019.100403. eCollection 2019 Sep.
7
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：免疫检查点抑制是转移性透明细胞肾细胞癌一线治疗的新支柱。
Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.
8
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.一线免疫检查点抑制剂治疗后采用二线 VEGFR-TKI 治疗转移性透明细胞肾细胞癌患者的结局。
Eur J Cancer. 2019 Jun;114:67-75. doi: 10.1016/j.ejca.2019.04.003. Epub 2019 May 7.
9
Towards individualized therapy for metastatic renal cell carcinoma.迈向转移性肾细胞癌的个体化治疗。
Nat Rev Clin Oncol. 2019 Oct;16(10):621-633. doi: 10.1038/s41571-019-0209-1.
10
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
Zotero 插件